CLPT ClearPoint Neuro, Inc.

Nasdaq clearpointneuro.com


$ 24.70 $ -0.53 (-2.1 %)    

Friday, 24-Oct-2025 16:15:56 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 24.74
$ 25.93
$ 24.74 x 35
$ 26.72 x 400
$ 24.74 - $ 26.72
$ 9.76 - $ 30.10
599,288
na
703.29M
$ 1.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 02-26-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-12-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-08-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-22-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 03-21-2018 12-31-2017 10-K
32 11-06-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-09-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-25-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clearpoint-neuro-shares-are-trading-higher-wednesday-whats-going-on

ClearPoint Neuro Inc. (NASDAQ:CLPT) shares are trading higher Wednesday after the company announced results from a Phase I-II c...

 clearpoint-neuro-reports-phase-i-ii-results-for-prism-laser-system-in-glioblastoma-study-improved-survival-compared-to-matched-open-surgery-controls-safe-feasible-and-reproducible-workflow-median-ablation-time-65-minutes

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...

 clearpoint-neuro-secures-regulatory-approvals-in-canada-hong-kong-and-taiwan-expanding-clinical-access-to-34-countries

The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards...

 clearpoint-neuro-unveils-robotic-neuro-navigation-system-to-advance-cell-and-gene-therapy-procedures

New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene TherapySOLANA BEACH, CALIFOR...

 why-pepgen-shares-are-trading-higher-by-112-here-are-20-stocks-moving-premarket

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...

 clearpoint-neuro-secures-fda-clearance-for-15t-mri-use-expanding-reach-for-prism-neuro-laser-system

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...

 clearpoint-neuro-affirms-fy2025-sales-guidance-of-36000m-41000m-vs-38150m-est

ClearPoint Neuro (NASDAQ:CLPT) affirms FY2025 sales outlook from $36.000 million-$41.000 million to $36.000 million-$41.000 mil...

 clearpoint-neuro-q2-eps-021-misses-018-estimate-sales-9215m-beat-9200m-estimate

ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(...

 clearpoint-neuro-achieves-key-milestones-with-first-us-commercial-gene-therapy-infusions-using-smartflow-device-for-aadc-deficiency

ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering pre...

 stifel-maintains-buy-on-clearpoint-neuro-raises-price-target-to-9

Stifel analyst Mathew Blackman maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and raises the price target from $8 to $9.

 on-june-16-2025-clearpoint-neuro-entered-into-a-lease-agreement-with--bre-bmr-scd-to-expand-into-approximately-30171-square-feet-within-a-life-science-building-located-in-san-diego-california

-SEC Filing

 clearpoint-neuro-reports-q1-earnings-revenue-beat-eps-miss-company-affirms-fy25-guidance

ClearPoint Neuro announces Q1 earnings, beating revenue estimates but missing earnings estimates. Company affirms full-year sal...

 clearpoint-neuro-affirms-fy2025-sales-guidance-of-3600m-4100m-vs-3823m-est

ClearPoint Neuro (NASDAQ:CLPT) affirms FY2025 sales outlook from $36.00 million-$41.00 million to $36.00 million-$41.00 million...

 clearpoint-neuro-q1-eps-022-misses-016-estimate-sales-848m-beat-820m-estimate

ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION